{"mainPropery":{"diseaseId":9778,"diseaseName":"CANOMAD syndrome","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9778/canomad-syndrome","synonyms":["Chronic Ataxic Neuropathy Ophthalmoplegia M-protein Agglutination Disialosyl antibodies syndrome","Chronic sensory ataxic neuropathy with anti-disialosyl antibodies"],"synonyms-with-source":[{"name":"Chronic Ataxic Neuropathy Ophthalmoplegia M-protein Agglutination Disialosyl antibodies syndrome"},{"name":"Chronic sensory ataxic neuropathy with anti-disialosyl antibodies"}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"71279"},{"identifierType":"UMLS","identifierId":"C2931684"}]},"diseaseCategories":[{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=CANOMAD%5BAll+Fields%5D' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss CANOMAD syndrome. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71279' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/Orphanet:71279' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":1698,"questionText":"What is CANOMAD syndrome?","answerText":"<strong>CANOMAD syndrome&nbsp;</strong>is a rare chronic immune-mediated demyelinating polyneuropathy. CANOMAD stands for Chronic Ataxic Neuropathy Ophthalmoplegia IgM paraprotein Cold Agglutinins Disialosyl antibodies. Signs and symptoms of CANOMAD may include loss of muscle, tendon, and joint sensation, abnormal gait (walk), <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003198.htm\" target=\"_blank\">ataxia</a>, tingling sensation on the skin around the mouth or extremities, paralysis of eye muscles, difficulty swallowing and speaking, and rarely respiratory muscle weakness. This condition is&nbsp;caused by&nbsp;the presence of anti-diasialosyl antibodies in the body.&nbsp; Oral or intravenous <a href=\"http://www.nlm.nih.gov/medlineplus/steroids.html\" target=\"_blank\">corticosteroids</a>, &szlig;-interferons, plasma exchange, intravenous immunoglobulin (IVIG), and <a href=\"http://www.aocd.org/skin/dermatologic_diseases/cytotoxic_drugs.html\" target=\"_blank\">cytotoxic</a> drugs have all been used in treating CANOMAD with varying success.[1008][1009][1010][1011][1012][11277]","dateModified":"2016-04-18T00:00:00"},"basicQuestions":[{"questionId":1695,"questionText":"What symptoms have been observed in patients with CANOMAD syndrome?","answerText":"<em>Willison et al.</em> (2001) described the signs, symptoms, and laboratory findings of 18 people with CANOMAD syndrome.&nbsp;This is the largest case series reported to date.&nbsp;The most prominent symptom&nbsp;experienced by the patients was the loss of kinesthesia. Kinesthesia refers to the perception of one's own body parts, weight, and movement. A loss of kinesthesia refers to the loss of sensation produced in <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/8956.htm\" target=\"_blank\">muscles, tendons</a> and <a href=\"http://www.nlm.nih.gov/medlineplus/bonesjointsandmuscles.html\" target=\"_blank\">joints</a>&nbsp;involved in movement. These patients&nbsp;presented with a distinct manner of walking (gait) and an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003198.htm\" target=\"_blank\">inability to coordinate</a> voluntary muscular movements in the upper limbs. This inability to coordinate muscle activity is called '<a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003198.htm\" target=\"_blank\">ataxia</a>'. These patients also experienced&nbsp;the feeling or sensation of pricking, tingling, or creeping on the skin in the tissues around the mouth (perioral) or extremities (acral).[1008]\r\n<p>The majority of the cases studied (16 out of the 18) also had motor and sensory <a href=\"http://www.merckmanuals.com/home/brain-spinal-cord-and-nerve-disorders/cranial-nerve-disorders/overview-of-the-cranial-nerves\" target=\"_blank\">cranial nerve</a> involvement, causing&nbsp;paralysis of some of the eye muscles (ophthalmoplegia), difficulty swallowing,&nbsp;difficulty articulating words&nbsp;and, rarely, respiratory muscle weakness.&nbsp; These symptoms were constant in some people, but&nbsp;for others the symptoms came and went.[1008]&nbsp;<br />\r\n<br />\r\nIn general, CANOMAD syndrome tends to have a chronic course that often extends over decades.[1012]</p>","dateModified":"2016-04-18T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":1008,"authors":"Willison, HJ et. al.,","articleTitle":"The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies","bookWebsiteJournalTitle":"Brain","date":"2001 Oct","volume":"124(Pt 10)","pages":"1968-77","url":"http://brain.oxfordjournals.org/content/124/10/1968.long","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1012,"authors":"Fontaine B","articleTitle":"CANOMAD syndrome","bookWebsiteJournalTitle":"Orphanet","date":"March 2007","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=71279","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1696,"questionText":"What causes CANOMAD syndrome?","answerText":"The underlying cause of CANOMAD syndrome is poorly understood. It appears as if IgM antibodies play a crucial role in the development of the disorder.[11278] It also appears as if the condition is&nbsp;caused in some way by the presence of anti-diasialosyl antibodies in the body. The source of anti-diasialosyl antibodies found in individuals with CANOMAD syndrome is unknown.[1008]","dateModified":"2016-04-18T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":1008,"authors":"Willison, HJ et. al.,","articleTitle":"The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies","bookWebsiteJournalTitle":"Brain","date":"2001 Oct","volume":"124(Pt 10)","pages":"1968-77","url":"http://brain.oxfordjournals.org/content/124/10/1968.long","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11278,"authors":"Krenn M, Keir G, Wieshmann UC","articleTitle":"CANOMAD responding to weekly treatment with intravenous immunoglobulin (IVIg)","bookWebsiteJournalTitle":"BMJ Case Rep","date":"2014 Apr 10","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987528/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1697,"questionText":"How might CANOMAD syndrome be treated?","answerText":"Oral or intravenous <a href=\"https://www.nlm.nih.gov/medlineplus/steroids.html\" target=\"_blank\">corticosteroids</a>, &szlig;-interferons, intravenous immunoglobulin (IVIG), plasma exchange,&nbsp;and <a href=\"http://www.aocd.org/skin/dermatologic_diseases/cytotoxic_drugs.html\" target=\"_blank\">cytotoxic</a> drugs&nbsp;and a combination of these therapies have all been used in treating CANOMAD syndrome with varying success.&nbsp;Their use, however, has not been evaluated systematically.[1008][1009][1010][1011][1012] In recent years, IVIG seems to be the preferred method of treatment.[11277][11278]","dateModified":"2016-04-18T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":1008,"authors":"Willison, HJ et. al.,","articleTitle":"The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies","bookWebsiteJournalTitle":"Brain","date":"2001 Oct","volume":"124(Pt 10)","pages":"1968-77","url":"http://brain.oxfordjournals.org/content/124/10/1968.long","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1009,"authors":"Scheinfeld NS","articleTitle":"Intravenous Immunoglobulin","bookWebsiteJournalTitle":"Medscape Reference","date":"February 3, 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/210367-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1010,"authors":"Arbogast SD, Khanna S, Koontz DW, Tomsak RL, Katirji B, Leigh RJ","articleTitle":"Chronic ataxic neuropathy mimicking dorsal midbrain syndrome","bookWebsiteJournalTitle":"J Neurol Neurosurg Psychiatry","date":"2007 Nov","volume":"78(11)","pages":"1276-7","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117616/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1011,"authors":"Relapsing sensorimotor neuropathy with ophthalmoplegia, antidisialosyl antibodies, and extramembranous glomerulonephritis","articleTitle":"Delval A, Stojkovic T, Vermersch P","bookWebsiteJournalTitle":"Muscle Nerve","date":"2006 Feb","volume":"33(2)","pages":"274-7","url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=16258949","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1012,"authors":"Fontaine B","articleTitle":"CANOMAD syndrome","bookWebsiteJournalTitle":"Orphanet","date":"March 2007","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=71279","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11277,"authors":"Johnson K, Malkan A, Shaffi M","articleTitle":"Facial Involuntary Movements and Respiratory Failure in CANOMAD, Responsive to IVIG Therapy","bookWebsiteJournalTitle":"Case Rep Med","date":"2015","volume":"2015","pages":"170543","url":"http://www.hindawi.com/journals/crim/2015/170543/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11278,"authors":"Krenn M, Keir G, Wieshmann UC","articleTitle":"CANOMAD responding to weekly treatment with intravenous immunoglobulin (IVIg)","bookWebsiteJournalTitle":"BMJ Case Rep","date":"2014 Apr 10","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987528/","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":23242,"abbreviatedInquiry":"I have had a very hard time finding information on CANOMAD. A loved one has had this condition for 4 years.&nbsp;I would like to learn more about it. ","caseQuestions":[{"questionId":1698,"questionText":"What is CANOMAD syndrome?","answerText":"<strong>CANOMAD syndrome&nbsp;</strong>is a rare chronic immune-mediated demyelinating polyneuropathy. CANOMAD stands for Chronic Ataxic Neuropathy Ophthalmoplegia IgM paraprotein Cold Agglutinins Disialosyl antibodies. Signs and symptoms of CANOMAD may include loss of muscle, tendon, and joint sensation, abnormal gait (walk), <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003198.htm\" target=\"_blank\">ataxia</a>, tingling sensation on the skin around the mouth or extremities, paralysis of eye muscles, difficulty swallowing and speaking, and rarely respiratory muscle weakness. This condition is&nbsp;caused by&nbsp;the presence of anti-diasialosyl antibodies in the body.&nbsp; Oral or intravenous <a href=\"http://www.nlm.nih.gov/medlineplus/steroids.html\" target=\"_blank\">corticosteroids</a>, &szlig;-interferons, plasma exchange, intravenous immunoglobulin (IVIG), and <a href=\"http://www.aocd.org/skin/dermatologic_diseases/cytotoxic_drugs.html\" target=\"_blank\">cytotoxic</a> drugs have all been used in treating CANOMAD with varying success.[1008][1009][1010][1011][1012][11277]","dateModified":"2016-04-18T00:00:00","references":[{"referenceId":1008,"authors":"Willison, HJ et. al.,","articleTitle":"The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies","bookWebsiteJournalTitle":"Brain","date":"2001 Oct","volume":"124(Pt 10)","pages":"1968-77","url":"http://brain.oxfordjournals.org/content/124/10/1968.long","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1009,"authors":"Scheinfeld NS","articleTitle":"Intravenous Immunoglobulin","bookWebsiteJournalTitle":"Medscape Reference","date":"February 3, 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/210367-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1010,"authors":"Arbogast SD, Khanna S, Koontz DW, Tomsak RL, Katirji B, Leigh RJ","articleTitle":"Chronic ataxic neuropathy mimicking dorsal midbrain syndrome","bookWebsiteJournalTitle":"J Neurol Neurosurg Psychiatry","date":"2007 Nov","volume":"78(11)","pages":"1276-7","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117616/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1011,"authors":"Relapsing sensorimotor neuropathy with ophthalmoplegia, antidisialosyl antibodies, and extramembranous glomerulonephritis","articleTitle":"Delval A, Stojkovic T, Vermersch P","bookWebsiteJournalTitle":"Muscle Nerve","date":"2006 Feb","volume":"33(2)","pages":"274-7","url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=16258949","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1012,"authors":"Fontaine B","articleTitle":"CANOMAD syndrome","bookWebsiteJournalTitle":"Orphanet","date":"March 2007","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=71279","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11277,"authors":"Johnson K, Malkan A, Shaffi M","articleTitle":"Facial Involuntary Movements and Respiratory Failure in CANOMAD, Responsive to IVIG Therapy","bookWebsiteJournalTitle":"Case Rep Med","date":"2015","volume":"2015","pages":"170543","url":"http://www.hindawi.com/journals/crim/2015/170543/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1693,"questionText":"Are there any medical terms that I should review prior to reading information about CANOMAD syndrome?","answerText":"It might be helpful to review the following descriptions before you read information about CANOMAD syndrome since most of the information available on the condition is very technical in nature.<br />\r\n<br />\r\n<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002312.htm\" target=\"_blank\">(C)hronic</a> - refers to the&nbsp;long duration of the condition.&nbsp;\r\n<p><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003198.htm\" target=\"_blank\">(A)taxic</a> - relates to the loss of ability to coordinate muscular movement.&nbsp; </p>\r\n<p><a href=\"http://www.emedicinehealth.com/neuropathy/article_em.htm\" target=\"_blank\">(N)europathy </a>- describes a disease or abnormality of the nervous system, especially one affecting the cranial or spinal nerves.</p>\r\n<p><a href=\"http://medical-dictionary.thefreedictionary.com/ophthalmoplegia\" target=\"_blank\">(O)phthalmoplegia</a> - refers to the paralysis of one or more of the muscles of the eye.</p>\r\n<p>Ig(M) paraprotein&nbsp;- IgM is a protein, more specifically an <a href=\"http://www.genome.gov/glossary.cfm?key=antibody\" target=\"_blank\">antibody</a>, that is secreted by plasma cells. Plasma cells are a pale yellow mixture of water, proteins and salts. One of the functions of plasma is to act as a carrier for blood cells, nutrients, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002353.htm\" target=\"_blank\">enzymes</a> and <a href=\"https://www.nlm.nih.gov/medlineplus/hormones.html\" target=\"_blank\">hormones</a>. In CANOMAD the IgM antibody is abnormally present. The term &ldquo;paraprotein&rdquo; actually refers to any abnormal plasma protein associated with a disease.</p>\r\n<p>Cold (A)gglutinins - antibodies that are active at cold temperatures, attaching to red blood cells and causing the red cells to bind together or 'agglutinate.'</p>\r\n<p>(D)isialosyl antibodies -&nbsp;in this disease, \"anti-disialosyl antibodies\"&nbsp;refers to the IgM antibodies.</p>","dateModified":"2016-04-18T00:00:00","references":[{"referenceId":1008,"authors":"Willison, HJ et. al.,","articleTitle":"The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies","bookWebsiteJournalTitle":"Brain","date":"2001 Oct","volume":"124(Pt 10)","pages":"1968-77","url":"http://brain.oxfordjournals.org/content/124/10/1968.long","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1009,"authors":"Scheinfeld NS","articleTitle":"Intravenous Immunoglobulin","bookWebsiteJournalTitle":"Medscape Reference","date":"February 3, 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/210367-overview","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1694,"questionText":"Why is there such limited information on CANOMAD syndrome?","answerText":"There have not been many documented cases of&nbsp;the condition as demonstrated by the presence of very few articles on CANOMAD syndrome&nbsp;in the medical literature.","dateModified":"2016-04-18T00:00:00","references":[]},{"questionId":1695,"questionText":"What symptoms have been observed in patients with CANOMAD syndrome?","answerText":"<em>Willison et al.</em> (2001) described the signs, symptoms, and laboratory findings of 18 people with CANOMAD syndrome.&nbsp;This is the largest case series reported to date.&nbsp;The most prominent symptom&nbsp;experienced by the patients was the loss of kinesthesia. Kinesthesia refers to the perception of one's own body parts, weight, and movement. A loss of kinesthesia refers to the loss of sensation produced in <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/8956.htm\" target=\"_blank\">muscles, tendons</a> and <a href=\"http://www.nlm.nih.gov/medlineplus/bonesjointsandmuscles.html\" target=\"_blank\">joints</a>&nbsp;involved in movement. These patients&nbsp;presented with a distinct manner of walking (gait) and an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003198.htm\" target=\"_blank\">inability to coordinate</a> voluntary muscular movements in the upper limbs. This inability to coordinate muscle activity is called '<a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003198.htm\" target=\"_blank\">ataxia</a>'. These patients also experienced&nbsp;the feeling or sensation of pricking, tingling, or creeping on the skin in the tissues around the mouth (perioral) or extremities (acral).[1008]\r\n<p>The majority of the cases studied (16 out of the 18) also had motor and sensory <a href=\"http://www.merckmanuals.com/home/brain-spinal-cord-and-nerve-disorders/cranial-nerve-disorders/overview-of-the-cranial-nerves\" target=\"_blank\">cranial nerve</a> involvement, causing&nbsp;paralysis of some of the eye muscles (ophthalmoplegia), difficulty swallowing,&nbsp;difficulty articulating words&nbsp;and, rarely, respiratory muscle weakness.&nbsp; These symptoms were constant in some people, but&nbsp;for others the symptoms came and went.[1008]&nbsp;<br />\r\n<br />\r\nIn general, CANOMAD syndrome tends to have a chronic course that often extends over decades.[1012]</p>","dateModified":"2016-04-18T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":1008,"authors":"Willison, HJ et. al.,","articleTitle":"The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies","bookWebsiteJournalTitle":"Brain","date":"2001 Oct","volume":"124(Pt 10)","pages":"1968-77","url":"http://brain.oxfordjournals.org/content/124/10/1968.long","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1012,"authors":"Fontaine B","articleTitle":"CANOMAD syndrome","bookWebsiteJournalTitle":"Orphanet","date":"March 2007","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=71279","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1696,"questionText":"What causes CANOMAD syndrome?","answerText":"The underlying cause of CANOMAD syndrome is poorly understood. It appears as if IgM antibodies play a crucial role in the development of the disorder.[11278] It also appears as if the condition is&nbsp;caused in some way by the presence of anti-diasialosyl antibodies in the body. The source of anti-diasialosyl antibodies found in individuals with CANOMAD syndrome is unknown.[1008]","dateModified":"2016-04-18T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":1008,"authors":"Willison, HJ et. al.,","articleTitle":"The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies","bookWebsiteJournalTitle":"Brain","date":"2001 Oct","volume":"124(Pt 10)","pages":"1968-77","url":"http://brain.oxfordjournals.org/content/124/10/1968.long","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11278,"authors":"Krenn M, Keir G, Wieshmann UC","articleTitle":"CANOMAD responding to weekly treatment with intravenous immunoglobulin (IVIg)","bookWebsiteJournalTitle":"BMJ Case Rep","date":"2014 Apr 10","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987528/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1697,"questionText":"How might CANOMAD syndrome be treated?","answerText":"Oral or intravenous <a href=\"https://www.nlm.nih.gov/medlineplus/steroids.html\" target=\"_blank\">corticosteroids</a>, &szlig;-interferons, intravenous immunoglobulin (IVIG), plasma exchange,&nbsp;and <a href=\"http://www.aocd.org/skin/dermatologic_diseases/cytotoxic_drugs.html\" target=\"_blank\">cytotoxic</a> drugs&nbsp;and a combination of these therapies have all been used in treating CANOMAD syndrome with varying success.&nbsp;Their use, however, has not been evaluated systematically.[1008][1009][1010][1011][1012] In recent years, IVIG seems to be the preferred method of treatment.[11277][11278]","dateModified":"2016-04-18T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":1008,"authors":"Willison, HJ et. al.,","articleTitle":"The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies","bookWebsiteJournalTitle":"Brain","date":"2001 Oct","volume":"124(Pt 10)","pages":"1968-77","url":"http://brain.oxfordjournals.org/content/124/10/1968.long","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1009,"authors":"Scheinfeld NS","articleTitle":"Intravenous Immunoglobulin","bookWebsiteJournalTitle":"Medscape Reference","date":"February 3, 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/210367-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1010,"authors":"Arbogast SD, Khanna S, Koontz DW, Tomsak RL, Katirji B, Leigh RJ","articleTitle":"Chronic ataxic neuropathy mimicking dorsal midbrain syndrome","bookWebsiteJournalTitle":"J Neurol Neurosurg Psychiatry","date":"2007 Nov","volume":"78(11)","pages":"1276-7","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117616/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1011,"authors":"Relapsing sensorimotor neuropathy with ophthalmoplegia, antidisialosyl antibodies, and extramembranous glomerulonephritis","articleTitle":"Delval A, Stojkovic T, Vermersch P","bookWebsiteJournalTitle":"Muscle Nerve","date":"2006 Feb","volume":"33(2)","pages":"274-7","url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=16258949","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1012,"authors":"Fontaine B","articleTitle":"CANOMAD syndrome","bookWebsiteJournalTitle":"Orphanet","date":"March 2007","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=71279","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11277,"authors":"Johnson K, Malkan A, Shaffi M","articleTitle":"Facial Involuntary Movements and Respiratory Failure in CANOMAD, Responsive to IVIG Therapy","bookWebsiteJournalTitle":"Case Rep Med","date":"2015","volume":"2015","pages":"170543","url":"http://www.hindawi.com/journals/crim/2015/170543/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11278,"authors":"Krenn M, Keir G, Wieshmann UC","articleTitle":"CANOMAD responding to weekly treatment with intravenous immunoglobulin (IVIg)","bookWebsiteJournalTitle":"BMJ Case Rep","date":"2014 Apr 10","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987528/","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"CANOMAD_syndrome"}